DGAP-Ad hoc: Vita 34 AG

Vita 34 adjusts revenues and earnings targets for 2017

Leipzig, 8 August, 2017 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the second largest stem cell bank in Europe, adjusts its outlook for the current financial year after the acquisition of former competitor Seracell. Against the backdrop of the initial consolidation of the business figures as of 28 June 2017, the Executive Board of Vita 34 AG now expects revenues between EUR 18.9 and 19.4 million (previously: EUR 17.4 - 17.9 m) and earnings before interest, taxes, depreciation and amortization (EBITDA) between EUR 1.6 to 1.9 million (previously: EUR 2.6 - 2.7 m).

The new targets already include all the one-time effects associated with the transaction. In detail, this includes transaction costs including costs of the capital increase of EUR 0.3 million as well as integration costs including severance payments and compensation payments of EUR 1.0 million. In addition, the company expects costs of management changes of EUR 0.6 million.

The Management Board expects to fully conclude the integration of Seracell in the current financial year. From 2018 onwards, therefore, the Management expects no further special effects resulting from the acquisition of Seracell. The company will publish the full-year outlook for 2018 in the first quarter of 2018 with the publication of the preliminary results for 2017.

Contact:

Ingo Middelmenne
Investor Relations

Vita 34 AG
Deutscher Platz 5a
04103 Leipzig

Phone: +49 (0341) 48792 - 0
Email: ingo.middelmenne@vita34.de